MPC·Green Cross·HumanN·Sell Materapeutics co-invited… “Vaccine technology transfer and production will be concretely planned”
[팍스넷뉴스 조재석 기자] Core personnel from the Chumakov Institute (hereinafter referred to as Chumakov Research Center) and Smart Biotech, who developed the Corona 19 vaccine’CoviVac’ approved by the Russian government, will visit Korea. This is to discuss domestic business realization with Moscow Partners Corporation (MPC), a business partner.
According to MPC on the 17th, for about a week from the 20th, the head of development and innovation industrial technology at Chumakoff Institute, the CEO of project management, as well as officials from Smart Biotech will visit Korea. The visit to Korea is in accordance with the joint invitation of MPC and Green Cross, as well as the domestic production participants of HumanN and Cella Therapeutics. It is known that Russian officials will visit domestic large-scale consignment manufacturing (CMO) companies and institutions that are working to meet annual output of more than 100 million doses during their visit to Korea and conduct consultations with business officials.
Particularly, the Smart Biotech officials in charge of global production and sales of Kobebak are planning to intensively check whether the entire process from vaccine development to production, commercialization, distribution, and other commercialization is systematically in progress.
Chumakoff Research Center is a national vaccine research institute that developed the first polio vaccine in Russia, and Smart Biotech is a Russian for-profit corporation established by Chumakov Research Center.
An MPC official explained, “The NDA was signed between the GC Green Cross and the Andong Animal Cell Demonstration Support Center, which is building the BSL3 production line, and for several months, we proceeded closely with discussions on the schedule of technology transfer and reinforcement of facilities, promoting this visit to Korea.” did. “Smart Biotech expects this visit to Korea as a starting point for practical cooperation with competitive companies for the domestic production of Kobe Bak.” He said that it will be a good opportunity to further increase the possibility of success in the business.”
The Corona 19 vaccine Kobivac, which is being developed by the Chumakov Research Center in Russia, is a type of inactivated vaccine and has been conditionally approved for showing superior therapeutic effects compared to other corona vaccines. As it is manufactured through a classical vaccine manufacturing method, expectations for stable efficacy are high compared to other Corona 19 vaccines based on a nucleic acid platform.
ⒸLook at the market with new eyes. Unauthorized distribution of Paxnet News is prohibited